STOCK TITAN

Citius Oncology grants Holubiak 300K stock options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Citius Oncology, Inc. (CTOR) reported option awards dated November 9, 2026, including 300,000 options granted to Secretary and director Myron Z. Holubiak and 50,000 options held by his daughter; Holubiak disclaims beneficial ownership of the latter. The options have an exercise price of $0.5495 per share and expire November 9, 2036.

The report also lists Holubiak’s existing options: 300,000 direct and 50,000 held by his daughter at $1.07 per share, expiring December 12, 2034, plus 1.5 million direct options at $2.15 per share, expiring July 5, 2033. He reported direct ownership of 850,000 common shares; 100,000 restricted stock awards are held by his daughter, and he disclaims beneficial ownership of those shares.

Insider HOLUBIAK MYRON Z
Role Secretary
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F2 300,000 $0.00 $0.00
Grant/Award Stock Option (Right to Buy) F2, F4 50,000 $0.00 $0.00
Holding Stock Option (Right to Buy) F3 -- -- --
Holding Stock Option (Right to Buy) F3, F4 -- -- --
Holding Stock Option (Right to Buy) F5 -- -- --
Holding Common Stock -- -- --
Holding Common Stock F1 -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 2,100,000 options, with 1,800,000 underlying shares of Common Stock (Direct); Stock Option (Right to Buy) — 100,000 options, with 50,000 underlying shares of Common Stock (Indirect, See footnote); Common Stock — 850,000 shares (Direct); Common Stock — 100,000 shares (Indirect, See footnote)
Footnotes (5)
  1. F1. Represents restricted stock awards granted on September 19, 2025 to the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares.
  2. F2. These options were granted on November 9, 2026. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
  3. F3. These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
  4. F4. These options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares.
  5. F5. These options vest over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
Options granted to Myron Z. Holubiak 300,000 options Award dated November 9, 2026
Options held by Holubiak’s daughter 50,000 options Award dated November 9, 2026; Holubiak disclaims beneficial ownership
Exercise price of new options $0.5495 per share Options dated November 9, 2026
Expiration of new options November 9, 2036 Options dated November 9, 2026
Existing direct options 300,000 underlying shares at $1.07 per share Expire December 12, 2034
Existing options held by daughter 50,000 underlying shares at $1.07 per share Expire December 12, 2034; Holubiak disclaims beneficial ownership
Other existing direct options 1,500,000 underlying shares at $2.15 per share Expire July 5, 2033
Direct common stock holdings 850,000 shares Reported as of November 9, 2026
Continuous Service technical
"subject to the Reporting Person’s Continuous Service to Citius Oncology, Inc."
restricted stock awards technical
"Represents restricted stock awards granted on September 19, 2025"
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What options did CTOR report for Myron Z. Holubiak?

The November 9, 2026 report lists 300,000 options granted to Secretary and director Myron Z. Holubiak and 50,000 options held by his daughter. Both have a $0.5495-per-share exercise price and expire November 9, 2036; Holubiak disclaims beneficial ownership of his daughter’s options.

When do CTOR’s November 2026 options vest?

The options vest one-third on each of the first, second and third anniversaries of the November 9, 2026 grant date, subject to Holubiak having Continuous Service to Citius Oncology or a Related Entity on each applicable vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HOLUBIAK MYRON Z

(Last)(First)(Middle)
C/O CITIUS ONCOLOGY, INC.
11 COMMERCE DRIVE, 1ST FLOOR

(Street)
CRANFORD NEW JERSEY 07016

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CITIUS ONCOLOGY, INC. [ CTOR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Secretary
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock850,000D
Common Stock100,000ISee footnote(1)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.549511/09/2026A300,000 (2)11/09/2036Common Stock300,000$0300,000D
Stock Option (Right to Buy)$0.549511/09/2026A50,000 (2)11/09/2036Common Stock50,000$050,000ISee footnote(4)
Stock Option (Right to Buy)$1.07 (3)12/12/2034Common Stock300,000300,000D
Stock Option (Right to Buy)$1.07 (3)12/12/2034Common Stock50,00050,000ISee footnote(4)
Stock Option (Right to Buy)$2.15 (5)07/05/2033Common Stock1,500,0001,500,000D
Explanation of Responses:
1. Represents restricted stock awards granted on September 19, 2025 to the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares.
2. These options were granted on November 9, 2026. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
3. These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
4. These options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares.
5. These options vest over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
/s/ Alexander M. Donaldson, by Power of Attorney11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading